Reblozyl 25 mg/1
Luspatercept · INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION · Celgene Corporation
Reblozyl is a injection, powder, lyophilized, for solution containing luspatercept at 25 mg/1, taken subcutaneous. Manufactured by Celgene Corporation.
Key Facts
- Brand Name
- Reblozyl
- Generic Name
- Luspatercept
- NDC Code (Product)
59572-711- Manufacturer
- Celgene Corporation
- Strength
- 25 mg/1
- Dosage Form
- INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
- Route
- SUBCUTANEOUS
- Marketing Status
- Application #
- BLA761136
- Drug Class
- Erythroid Maturation Agent [EPC]
- Marketing Start
- 11/08/2019
Recall History
No Recall HistoryFrequently Asked Questions
What is Reblozyl used for?
Reblozyl contains Luspatercept. It is a injection, powder, lyophilized, for solution taken subcutaneous. Consult your doctor for specific uses.
Is Reblozyl a controlled substance?
Reblozyl is not classified as a controlled substance by the DEA.
What is the generic name for Reblozyl?
The generic name for Reblozyl is Luspatercept. There are no other listed brand versions of Luspatercept.
What is the NDC code for Reblozyl 25 mg/1?
The NDC (National Drug Code) for Reblozyl 25 mg/1 is 59572-711, listed by Celgene Corporation.
Other Reblozyl Dosages
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)